{"protocolSection":{"identificationModule":{"nctId":"NCT04916197","orgStudyIdInfo":{"id":"00375929"},"organization":{"fullName":"Beijing Chao Yang Hospital","class":"OTHER"},"briefTitle":"Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With EVT on Long-term Prognosis in Patients With AIS (PPDET)","officialTitle":"Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With Endovascular Thrombectomy on Long-term Prognosis in Patients With Acute Ischemic Stroke (PPDET)"},"statusModule":{"statusVerifiedDate":"2023-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-03-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-05-25","studyFirstSubmitQcDate":"2021-06-03","studyFirstPostDateStruct":{"date":"2021-06-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-12-19","lastUpdatePostDateStruct":{"date":"2023-12-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Changwei Wei","investigatorTitle":"Deputy chief physician","investigatorAffiliation":"Beijing Chao Yang Hospital"},"leadSponsor":{"name":"Beijing Chao Yang Hospital","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. The investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients.","detailedDescription":"Endovascular treatment with mechanical thrombectomy is the standard treatment for acute large vessel occlusion.\n\nDexmedetomidine is a commonly used sedative in endovascular thrombectomy of acute ischemic stroke.\n\nDexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury.\n\nThe investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Endovascular thrombectomy","Dexmedetomidine","Modified Rankin Scale"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":368,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intervention group","type":"EXPERIMENTAL","description":"Dexmedetomidine 0.1\\~1.0 μg/kg/h for 24h after patients finished endovascular thrombectomy and returned to ICU. Maintain Ramsay score 2-3.","interventionNames":["Drug: Dexmedetomidine prolonged sedation"]},{"label":"Control group","type":"PLACEBO_COMPARATOR","description":"An equal dose of saline 24h after patients finished endovascular thrombectomy and returned to ICU. If the Ramsay sedation score is 1, propofol will be administrated to maintain the Ramsay sedation score at 2 to 3.","interventionNames":["Drug: 0.9% saline"]}],"interventions":[{"type":"DRUG","name":"Dexmedetomidine prolonged sedation","description":"Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.","armGroupLabels":["Intervention group"]},{"type":"DRUG","name":"0.9% saline","description":"An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.","armGroupLabels":["Control group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The favorable functional outcome of stroke-related disability rate","description":"Modified Rankin Scale ≤ 2 points. mRS range from 0 to 6, higher scores mean a worse outcome.","timeFrame":"90 ± 14 days after thrombectomy"}],"secondaryOutcomes":[{"measure":"Changes of National Institute of Health stroke scale","description":"NIHSS (admission) - NIHSS (24h)","timeFrame":"24 ± 6 hours after thrombectomy"},{"measure":"Changes of National Institute of Health stroke scale","description":"NIHSS (admission) - NIHSS (7day)","timeFrame":"on the 7-day or discharged day whichever comes first, up to 30 days"},{"measure":"Changes of ischemic penumbra","description":"The difference of infarct volume between preoperative and 7-day or discharged day","timeFrame":"on the 7-day or discharged day whichever comes first, up to 30 days"},{"measure":"Length of ICU stay","description":"Length of ICU stay","timeFrame":"From the date of admission until discharged from ICU, up to 30 days"},{"measure":"Length of hospital stay","description":"Length of hospital stay","timeFrame":"From the date of admission until discharged from hospital, up to 30 days"},{"measure":"adverse events at 90-day after operation","description":"hypotension (systolic blood pressure under 90mmHg), bradycardia (heart rate under 50bpm), hypoxemia (pulse oxygen saturation under 90%), and serious events such as death and life-threatening events","timeFrame":"within 90-day after thrombectomy"},{"measure":"mortality rate at 90-day after operation","description":"Death after thrombectomy within 90-day after operation","timeFrame":"within 90-day after thrombectomy"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 2≤NIHSS≤25\n* mRS score before stroke was less than 3\n* Acute ischemic stroke (including anterior circulation)\n* mTICI rate 2b or 3\n* According to the 2018 AHA/ASA guidelines for the management of acute ischemic stroke, patients who plan to receive mechanical thrombectomy under local anesthesia and sedation\n* Informed consent was signed by patient or legal representative\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage occurred in the responsible vessel area in the past 6 weeks\n* Patients who had received stent treatment at the responsible vessel in the past\n* Neurological function was restored at or before angiography\n* Patients who are allergic to heparin, aspirin, clopidogrel, rapamycin, lactic acid polymer, poly (n-butyl methacrylate), stainless steel, anesthetics and contrast agents or have contraindications\n* Hemoglobin was less than 70g/L, platelet count was less than 50×109/L, international normalized ratio (INR) greater than 1.5 (irreversible), there are uncorrectable bleeding factors\n* Blood glucose \\< 2.7 mmol/L or \\> 22.2 mmol/L\n* Severe liver or kidney disfunction, ALT\\>3 times the upper limit of normal value or AST\\>3 times the upper limit of normal value, creatinine\\>1.5 times the upper limit of normal value\n* Pregnant or lactating women\n* Previous history of mental illness\n* Stroke with other acute diseases or postoperative stroke of other operation\n* Heart rate less than 50bpm, second or third degree of atrioventricular block (except for pacemaker implantation), systolic blood pressure less than 90mmHg (two vasoactive drugs were already infused continuously )","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Lina Yang","role":"CONTACT","phone":"18611635556","email":"Thoth_safin@sina.com"}],"locations":[{"facility":"Beijing ChaoYang Hospital","status":"RECRUITING","city":"Beijing","state":"Beijing","zip":"100020","country":"China","contacts":[{"name":"Lina Yang","role":"CONTACT","phone":"18611635556","email":"Thoth_safin@sina.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The study protocol and Informed Consent Form will be shared with other researchers.","infoTypes":["STUDY_PROTOCOL","ICF"],"timeFrame":"The information will become available after the publishing of this study and will be available for 1-year after publishing.","accessCriteria":"Please contact by E-mail at thoth_safin@sina.com"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000020927","term":"Dexmedetomidine"}],"ancestors":[{"id":"D000006993","term":"Hypnotics and Sedatives"},{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000058647","term":"Adrenergic alpha-2 Receptor Agonists"},{"id":"D000000316","term":"Adrenergic alpha-Agonists"},{"id":"D000000322","term":"Adrenergic Agonists"},{"id":"D000018663","term":"Adrenergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M22352","name":"Dexmedetomidine","asFound":"Combined","relevance":"HIGH"},{"id":"M17997","name":"Propofol","relevance":"LOW"},{"id":"M4544","name":"Benzocaine","relevance":"LOW"},{"id":"M9733","name":"Hypnotics and Sedatives","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20436","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M3358","name":"Adrenergic alpha-Agonists","relevance":"LOW"},{"id":"M3363","name":"Adrenergic Agonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"T433","name":"Tannic Acid","relevance":"LOW"}],"browseBranches":[{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":false}